You are in: eMedicine Specialties > Ophthalmology > CONJUNCTIVA Conjunctivitis, BacterialArticle Last Updated: May 10, 2007AUTHOR AND EDITOR INFORMATIONAuthor: David S Marlin, MD, Consulting Staff, Department of Ophthalmology, Kaiser Foundation Hospital, Los Angeles Medical Center Editors: Jerre Freeman, MD, Founder, Chairman, Memphis Eye and Cataract Associates; Clinical Professor, Department of Ophthalmology, University of Tennessee Health Science Center; Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles; Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Jefferson Medical College; Co-Chairman of the Cornea Service, Co-Chairman of Refractive Surgery Department, Wills Eye Hospital; Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri; Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences Author and Editor Disclosure Synonyms and related keywords: bacterial conjunctivitis, eye infection, pink eye, red eye INTRODUCTIONBackgroundBacterial conjunctivitis is a microbial infection involving the mucous membrane of the surface of the eye. This condition, which is usually a benign self-limited illness, sometimes can be serious or signify a severe underlying systemic disease. Occasionally, significant ocular and systemic morbidity may result. PathophysiologyThe surface tissues of the eye and the ocular adnexa are colonized by normal flora such as streptococci, staphylococci, and Corynebacterium strains. Alterations in the host defense or in the species of bacteria can lead to clinical infection. An alteration in the flora can occur by external contamination, by spread from adjacent sites, or via a blood-borne pathway. The primary defense against infection is the epithelial layer covering the conjunctiva. Disruption of this barrier can lead to infection. Secondary defenses include hematologic immune mechanisms carried by the conjunctival vasculature; tear film immunoglobulins and lysozyme; and the rinsing action of lacrimation and blinking. FrequencyUnited StatesBacterial conjunctivitis is a common condition in all areas of the United States. It is likely that most people will experience an episode. Most of the benign cases probably are treated by primary physicians or resolve spontaneously. InternationalBacterial conjunctivitis is common worldwide. Community sequelae can be devastating in areas affected by blinding infections of newborns as well as in areas heavily affected by Chlamydia trachomatis. Mortality/MorbidityMortality in the setting of bacterial conjunctivitis is related to the failure to recognize and treat the underlying disease. Sepsis and meningitis caused by Neisseria gonorrhoeae can be life threatening. Chlamydial infection in the newborn can lead to pneumonia and/or otitis media. Morbidity in terms of discomfort, ocular discharge, and redness are common in benign cases and often lead to absence from work and school. Morbidity can be associated with misdiagnosis. Since many eye diseases cause the eye to be red, it is beneficial to have a solid approach to diagnosis. Race
Sex
Age
CLINICALHistoryEliciting a clinical history from the patient is influenced by such factors as age and social habits and may occasionally focus on sensitive issues that can be embarrassing to discuss.
PhysicalThe physical examination should evaluate the following signs:
Causes
DIFFERENTIALSBlepharitis, Adult Cellulitis, Preseptal Chlamydia Conjunctivitis, Acute Hemorrhagic Conjunctivitis, Allergic Conjunctivitis, Giant Papillary Conjunctivitis, Neonatal Conjunctivitis, Viral Contact Lens Complications Corneal Foreign Body Corneal Graft Rejection Dacryocystitis Endophthalmitis, Bacterial Endophthalmitis, Fungal Endophthalmitis, Postoperative Episcleritis Filtering Bleb Complications Fistula, Carotid Cavernous Glaucoma, Angle Closure, Acute Glaucoma, Malignant Glaucoma, Neovascular Glaucoma, Uveitic Gonococcus Herpes Simplex Herpes Zoster Hordeolum Horner Syndrome Keratitis, Bacterial Keratitis, Fungal Keratitis, Herpes Simplex Keratoconjunctivitis, Epidemic Keratoconjunctivitis, Superior Limbic Molluscum Contagiosum Ocular Rosacea Pharyngoconjunctival Fever Scleritis Squamous Cell Carcinoma, Conjunctival Subconjunctival Hemorrhage Thyroid Ophthalmopathy Trachoma Trichiasis Uveitis, Anterior, Granulomatous
|
| Drug Name | Sodium sulfacetamide (Bleph-10, Cetamide, AK-Sulf) |
|---|---|
| Description | Effective in most cases of bacterial conjunctivitis including those caused by Streptococcus pneumoniae, Haemophilus influenzae, and group A Streptococcus pyogenes. It may have some local activity against Chlamydia. Available as a solution and ointment preparation. |
| Adult Dose | Solution (10%): Instill 1-3 gtt q2-3h in affected eye, while awake, for 1 wk with less frequent administration at night Ointment: Apply 0.5-ribbon into conjunctival sac qid for 1 wk |
| Pediatric Dose | Administer as in adults; sometimes 5% preparation used |
| Contraindications | Documented hypersensitivity |
| Interactions | Effects decreased when used concurrently with gentamicin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Practitioners should be aware of the toxicity of systemically administered sulfonamides including the rare hematologic effects of agranulocytosis and hemolytic anemia; therefore, it is advisable to treat only if clinically indicated; caution in severely dried eye; ointment may retard corneal epithelial healing |
| Drug Name | Gentamicin (Genoptic, Ocumycin) |
|---|---|
| Description | Aminoglycoside antibiotic used for gram-negative bacterial coverage. Most cases of bacterial conjunctivitis will respond to this agent including pseudomonads, Staphylococcus aureus, group A streptococci, S pneumoniae, and H influenzae. Commercially available in solution or ointment form. |
| Adult Dose | Ointment: Apply 0.5-inch (1/25 cm) ribbon to affected eye(s) qid for 1 wk Solution: Instill 1-2 gtt qid for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; mycobacterial, viral, and fungal infections of the eye; steroid combinations after uncomplicated removal of a foreign body from cornea also should avoid using this product |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use to treat ocular infections that may become systemic; prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and may lead to a secondary infections |
| Drug Name | Erythromycin ointment (E-Mycin) |
|---|---|
| Description | Indicated for infections caused by susceptible strains of microorganisms and for prevention of corneal and conjunctival infections. Effective in most cases of bacterial conjunctivitis including those caused by S aureus, group A streptococci, S pneumoniae, and H influenzae. |
| Adult Dose | Apply 0.5-inch (1.25 cm) ribbon qid for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, mycobacterial, fungal infections of eye; patients using steroid combinations after uncomplicated removal of a foreign body from cornea also should avoid using this product |
| Interactions | None reported |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Do not use topical antibiotics to treat ocular infections that may become systemic; prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and may lead to a secondary infection (take appropriate measures if superinfection occurs); may not cover pseudomonads in the setting of immunocompromised patients |
| Drug Name | Azithromycin ophthalmic (AzaSite) |
|---|---|
| Description | Ophthalmic macrolide antibiotic. Indicated for bacterial conjunctivitis caused by CDC coryneform group G bacteria, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae. |
| Adult Dose | Instill 1 gtt in affected eye(s) bid (administer doses 8-12 h apart) for 2 d, then 1 gtt qd for next 5 d |
| Pediatric Dose | <1 year: Not established >1 year: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Usually safe but benefits must outweigh the risks |
| Precautions | Thoroughly wash hands before using; for topical ophthalmic use only; prolonged use may result in resistant organisms; do not wear contact lenses until infection resolves; may cause eye irritation; less common adverse effects include burning, stinging, and/or irritation when instilled; other less common adverse effects include contact dermatitis, corneal erosion, dry eyes, dysgeusia, nasal congestion, ocular discharge, punctate keratitis, and sinusitis |
| Drug Name | Bacitracin (AK-Tracin, Baciguent) |
|---|---|
| Description | Prevents transfer of mucopeptides into growing cell wall, inhibiting bacterial growth. Most cases of routine bacterial conjunctivitis will respond to bacitracin including those caused by group A streptococci, S aureus, S pneumoniae, and H influenzae. |
| Adult Dose | Apply 0.25- to 0.5-inch ribbon bid/qid into conjunctival sac(s) for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; vaccinia, varicella, epithelial herpes simplex keratitis, mycobacterial infections, fungal diseases of the eye; patients using steroid combinations after uncomplicated removal of a corneal foreign body |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Ophthalmic ointments may delay healing of corneal epithelia; in deep-seated infections of the eye, supplement with systemic medications; prolonged use may result in overgrowth of nonsusceptible organisms |
| Drug Name | Ciprofloxacin (Ciloxan) |
|---|---|
| Description | Inhibits bacterial growth by inhibiting DNA gyrase. Indicated for superficial ocular infections of the conjunctiva or cornea caused by strains of microorganisms susceptible to ciprofloxacin. They are effective in most cases of routine conjunctivitis including those caused by S aureus, group A streptococci, H influenzae, and Pseudomonas aeruginosa. They may not cover all cases of S pneumoniae. Newer classes of fluoroquinolones (eg, gatifloxacin, moxifloxacin) are available and are sometimes used for conjunctivitis or a red eye, particularly in the perioperative period for eye surgery. |
| Adult Dose | 1-2 gtt in the eye(s) qid for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, mycobacterial, and fungal eye infections; avoid coadministration with steroid combinations after uncomplicated removal of a foreign body from cornea |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Practitioners should be aware that the fluoroquinolones are not as effective against Pneumococcus as they are against other bacteria; do not use in ocular infections that may become systemic; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Trimethoprim and polymyxin B (Polytrim) |
|---|---|
| Description | For ocular infections, involving cornea or conjunctiva, resulting from strains of microorganisms susceptible to this antibiotic. Available as a solution and ointment. This combination of drugs is effective against the common causes of bacterial conjunctivitis including group A streptococci, S aureus, H influenzae, S pneumoniae, and pseudomonads. |
| Adult Dose | Solution: 1-2 gtt qid for 1 wk Ointment: 0.5-ribbon into conjunctival sac qid for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, fungal, and mycobacterial infections of the eye |
| Interactions | None reported |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Do not use in deep ocular infections or in those likely to become systemic; prolonged use of antibiotics, or repeated therapy, may result in bacterial or fungal overgrowth of nonsusceptible organism |
| Drug Name | Erythromycin (EES, Ery-Tab, Erythrocin) |
|---|---|
| Description | Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes causing RNA-dependent protein synthesis to arrest. Effective in the treatment of chlamydial infections. |
| Adult Dose | Adults are treated with doxycycline |
| Pediatric Dose | 50 mg/kg/d PO divided qid for 2 wk |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI side effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
| Drug Name | Doxycycline (Bio-Tab, Vibramycin, Doryx) |
|---|---|
| Description | Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Doxycycline is a tetracycline class of antibiotic that is effective in the treatment of adult chlamydial infections. |
| Adult Dose | 100 mg PO bid for 7-21 d |
| Pediatric Dose | Not prescribed for pediatric patients |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Penicillin G (Pfizerpen) |
|---|---|
| Description | Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms. Used in the hospital setting for neonatal gonorrheal infections. |
| Adult Dose | Adults use ceftriaxone/doxycycline regimen |
| Pediatric Dose | 100 U/kg/d IV divided qid for 1 wk |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid can increase effects of penicillin; coadministration of tetracyclines can decrease effects of penicillin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in impaired renal function and in the setting of seizure disorders |
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin that is an adjunct in the treatment of adult gonorrhea infections. Arrests bacterial growth by binding to one or more penicillin-binding proteins. |
| Adult Dose | 125 mg IM single dose, followed by a 1-wk course of doxycycline 100 PO bid for 7-21 d |
| Pediatric Dose | Not for use in pediatric population |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy; caution in breastfeeding women and in the setting of renal disease or seizure disorders |
| Drug Name | Tobramycin (Tobrex) |
|---|---|
| Description | Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, which results in a defective bacterial cell membrane. Available as a solution, ointment, and lotion. |
| Adult Dose | Solution: 1-2 gtt qid for 1 wk Ointment: Apply 0.5-inch ribbon in conjunctival sac bid/tid qid for 1 wk |
| Pediatric Dose | <2 years: Not established >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; mycobacterial, viral, and fungal infections of the eye; steroid combinations after uncomplicated removal of a foreign body from cornea also should avoid using this product |
| Interactions | Effects decrease when used concurrently with gentamicin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use in deep-seated ocular infections or in those that may become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms |
| Drug Name | Neomycin (Mycifradin) |
|---|---|
| Description | Used in the treatment of minor infections. Inhibits bacterial protein synthesis and growth. |
| Adult Dose | Apply 0.5-inch (1/25 cm) ribbon to affected eye(s) qid for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Absorption of neomycin is possible and may cause nephrotoxicity and ototoxicity; prolonged use may result in overgrowth of nonsusceptible organisms; may irritate ocular surface, resulting in mild injection of the conjunctiva and punctate staining of the cornea |
| Drug Name | Ofloxacin (Ocuflox) |
|---|---|
| Description | Pyridine carboxylic acid derivative with broad-spectrum bactericidal effect. Inhibits bacterial growth by inhibiting DNA gyrase. Indicated for superficial ocular infections of the conjunctiva or cornea caused by strains of microorganisms susceptible to ofloxacin. |
| Adult Dose | 1-2 gtt in affected eye(s) qid for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Failure to respond after treating for 2-3 d may indicate presence of resistant organism or another causative agent; do not use in ocular infections that may become systemic; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Levofloxacin (Quixin) |
|---|---|
| Description | S (-) enantiomer of ofloxacin. Inhibits DNA gyrase in susceptible organisms, thereby inhibiting relaxation of supercoiled DNA and promoting breakage of DNA strands. |
| Adult Dose | 1-2 gtt in affected eye(s) qid for 1 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Failure to respond after treating for 2-3 d may indicate presence of resistant organism or another causative agent; do not use in ocular infections that may become systemic; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Gatifloxacin ophthalmic solution 0.3% (Zymar) |
|---|---|
| Description | Fourth-generation fluoroquinolone ophthalmic indicated for bacterial conjunctivitis. Elicits a dual mechanism of action by possessing an 8-methoxy group, thereby inhibiting the enzymes DNA gyrase and topoisomerase IV. DNA gyrase is involved in bacterial DNA replication, transcription, and repair. Topoisomerase IV is essential in chromosomal DNA partitioning during bacterial cell division. Indicated for bacterial conjunctivitis due to Corynebacterium propinquum, S aureus, Staphylococcus epidermidis, Streptococcus mitis, S pneumoniae, or H influenzae. |
| Adult Dose | Days 1-2: Instill 1 gtt into affected eye(s) q2h while awake; not to exceed 8 administrations/d Days 3-7: Instill 1 gtt into affected eye(s) up to 4 times/d while awake |
| Pediatric Dose | <1 year: Not established >1 year: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | For ophthalmic use only; commonly causes conjunctival irritation, increased lacrimation, corneal inflammation, and papillary conjunctivitis; less common adverse effects include conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid swelling, headache, red eye, reduced visual acuity, and taste disturbance |
Conjunctivitis, Bacterial excerpt
Article Last Updated: May 10, 2007